Comparison of Two Chemotheropy Regimens (CHOP and COP) for Non-Hodgkin's Lymphoma

Abstract

Comparison of Two Chemotheropy Regimens (CHOP and COP) for Non-Hodgkin's Lymphoma

Saowanee      Chutipong                  MD

Anchalee Boonyaritipong         MD

Petch              Rawdaree                   MD

Department of Medicine, BMA Medical College and Vajira Hospital

Objective: To study efficacy of chemotherapy CHOP and COP in non-Hodgkin's lymphoma (NHL) by median     survival time and mortality rate,

Study design: Cohort study.

Subjects: Eighty sevent patients of intermediate and high grade NHL who attend in hematology clinic, Department of Medicine, BMA Medical College and Vajira Hospital from January 1985 to March 2000.

Methods: Follow up the patients who were intermediate and high grade NHL treated continuously by CHOP regimen (cyclophosphamide, doxorubicin, vencristine and prednisolone) every month in the first group.  And the second groups were treated continuously by COP regimen (cyclophosphamide, vincristine and prednisolone every month for two years.  Every patient were followed up about 55 months (average).

Main outcome measures: Median survival time and crude mortality rate.

Results: Median survival time of CHOP group is 28 months whereas 44 months in COP group but there was no statistically significant difference (p = 0.19).  The crude mortality rate in CHOP group was higher than in COP patients 1.901 time, but there was no statistically significant difference (p = 0.35).  When they were adjust Kaplan-Miere curve of survival by age group and staging there was statistically significant difference, by grading there was no statistically significant difference.

Conclusion: Median survival time and crude mortality rate in this study showed no difference in efficacy of CHOP and COP treatment.  When they were adjust Kaplan-Miere curve of survival by age group and staging there was statistically significant difference, by grading there was no statistically significant difference.

Key words: non-Hodgkin's lymphoma, chemotherapy

Vajira Med J 2001 ; 45 : 13 - 20